Business Context and Reporting Period
This Form 8-K was filed by EyeGate Pharmaceuticals, Inc. (trading symbol: EYEG) on September 23, 2019. The registrant is a Delaware corporation and an emerging growth company. The report addresses a specific corporate event regarding its listing status on The Nasdaq Capital Market.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on regulatory compliance status rather than financial performance.
Material Changes
The primary material event reported is the Company's regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). On September 23, 2019, EyeGate Pharmaceuticals received official notice from The Nasdaq Stock Market LLC confirming this status.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. No specific risks or contingencies are detailed in this document beyond the prior non-compliance issue which has now been resolved. The report incorporates a press release as Exhibit 99.1 for further details.
Investor Verification Checklist
- Verify the current trading status of EYEG on The Nasdaq Capital Market.
- Review the attached press release (Exhibit 99.1) for the specific bid price levels achieved to regain compliance.
- Confirm the Company's continued status as an emerging growth company and its election regarding extended transition periods for accounting standards.